aldosterone has been researched along with azelnidipine in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ikeda, K; Inada, Y; Isaka, T; Tajima, N; Takada, Y; Tojo, K | 1 |
| Du, J; Fan, YY; Fu, H; Fujisawa, Y; Hitomi, H; Hosomi, N; Kimura, S; Kiyomoto, H; Kohno, M; Lu, XM; Nagai, Y; Nakano, D; Nishiyama, A; Ohmori, K | 1 |
| Araki, E; Goto, R; Kondo, T; Miyamura, N; Ono, K; Sonoda, K; Takaki, Y; Yasuda, T; Yatsuda, R | 1 |
| Eguchi, K; Ishikawa, J; Kario, K; Matsui, Y; O'Rourke, MF; Shimada, K | 1 |
| Abe, M; Maruyama, N; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M | 1 |
2 trial(s) available for aldosterone and azelnidipine
| Article | Year |
|---|---|
Association between aldosterone induced by antihypertensive medication and arterial stiffness reduction: the J-CORE study.
Topics: Aged; Aldosterone; Antihypertensive Agents; Aorta; Azetidinecarboxylic Acid; Blood Flow Velocity; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Imidazoles; Male; Pulsatile Flow; Tetrazoles; Vascular Resistance | 2011 |
Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Tetrazoles | 2011 |
3 other study(ies) available for aldosterone and azelnidipine
| Article | Year |
|---|---|
Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aldosterone; Angiotensin II; Azetidinecarboxylic Acid; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cell Line, Tumor; Cytochrome P-450 CYP11B2; Dihydropyridines; Gene Expression Regulation; Humans; Nitrophenols; Organophosphorus Compounds; Potassium Chloride; Steroid 11-beta-Hydroxylase | 2009 |
Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats.
Topics: Aldosterone; Animals; Azetidinecarboxylic Acid; Blood Pressure; Body Weight; Calcium Channel Blockers; Collagen Type IV; Connective Tissue Growth Factor; Creatinine; Dihydropyridines; Ethidium; Gene Expression; Kidney; Kidney Diseases; Male; Mesangial Cells; NADPH Oxidases; Organ Size; Proteinuria; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Thiobarbituric Acid Reactive Substances; Transforming Growth Factor beta | 2009 |
Plasma renin activity and aldosterone concentration are not altered by the novel calcium channel antagonist, azelnidipine, in hypertensive patients.
Topics: Aged; Aged, 80 and over; Aldosterone; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Renin | 2010 |